• Niclosamide STAT3 Research Workflows

  2026-09-11

  Niclosamide connects STAT3 Tyr-705 inhibition with apoptosis, cell-cycle, and NF-κB readouts in cancer research. This workflow also uses ATRX-stratified glioma findings to improve comparative screening without overstating evidence for cross-pathway combinations.

• Ribociclib Succinate: From CDK4/6 Biology to Translation

  2026-09-11

  A translational framework for using LEE011 succinate as a CDK inhibitor: connect cell cycle regulation, orthogonal assay design, pH-aware formulation, and breast cancer research strategy without confusing in vitro activity with clinical exposure.

• MK-0812 CCR2 Inhibition in MASH Research

  2026-09-10

  MK-0812, also written MK0812, is a selective CCR2 antagonist that inhibits MCP-1 responses in human and rhesus blood models. It provides a pharmacological framework for testing monocyte trafficking in gut–liver axis studies, but direct efficacy in TM6SF2-driven MASH remains unestablished.

• PDK4 Inhibitors: Innovation and Translational Evidence

  2026-09-10

  The reference study used anthraquinone-based structural optimization to identify compound 8c, an allosteric PDK4 inhibitor with nanomolar biochemical activity and activity across metabolic, allergic, and cancer-related models. Its integrated biochemical, pharmacokinetic, in vivo, cellular, and docking data provide a useful framework for evaluating PDK4 inhibitors while also highlighting the limitations of early translational evidence.

• 11β-HSD1 Inhibition in Liver Fibrosis: Notch and NK

  2026-09-09

  The reference study identifies a dual mechanism by which 11β-HSD1 inhibition alleviates liver fibrosis: reduced cortisol-linked hepatic stellate cell activation, suppression of Notch signaling, and enhanced natural killer cell responses. Its integrated use of fibrosis measurements, transcriptomics, and mass cytometry provides a useful framework for evaluating immunometabolic antifibrotic strategies.

• Nuclear cGAS Restricts LINE-1 Retrotransposition

  2026-09-08

  The reference study identifies a nuclear cGAS–CHK2–TRIM41 pathway that limits LINE-1 retrotransposition by promoting ubiquitination and degradation of the essential L1 protein ORF2p. Its findings connect DNA damage signaling with post-translational control of mobile genetic elements, offering a mechanistic framework for studying genome instability, cellular senescence, and tumorigenesis.

• Ribociclib succinate: Reliable CDK4/6 Assays

  2026-09-08

  This scenario-driven guide shows how Ribociclib succinate, SKU B1084, can improve interpretation of cell proliferation, viability, and cytotoxicity assays through controlled solvent handling, pH-aware preparation, and orthogonal readouts. It connects CDK4/6 biology with practical assay design, product selection, and reproducibility limits.

• MLKL Polymerization and Lysosomal Membrane Permeabilization

  2026-09-07

  The reference study identifies MLKL polymerization-induced lysosomal membrane permeabilization as a key execution step in necroptosis. Its imaging, genetic, and pharmacological evidence places lysosomal cathepsin B release between MLKL activation and plasma membrane rupture, offering a more precise framework for studying regulated inflammatory cell death.

• Se-Methylselenocysteine, NRF2, and Ferroptosis in PDAC

  2026-09-07

  A 2026 study shows that Se-methylselenocysteine reprograms NRF2-, ATF4-, redox-, and ferroptosis-associated pathways in pancreatic ductal adenocarcinoma cells in a KYAT1-dependent and phenotype-specific manner. Its findings define a framework for connecting selenium metabolism with oxidative stress adaptation and ferroptosis vulnerability in pancreatic cancer research.

• Cell Counting Kit-8 Plus: Mechanism and Workflow

  2026-09-05

  Cell Counting Kit-8 Plus is a sensitive tetrazolium salt assay for measuring viable-cell metabolic activity in proliferation, cytotoxicity, and drug-screening workflows. Its WST-8 chemistry provides a soluble formazan readout, while the linked ccRCC study shows why metabolic context must be considered when interpreting viability data.

• Netarsudil: ROCK Inhibition and siRNA Workflows

  2026-09-04

  Netarsudil (AR-13324) combines potent ROCK-pathway pharmacology with a distinctive opportunity for siRNA nanoparticle codelivery. This article translates that dual use-case into practical trabecular meshwork assays, formulation screens, controls, and troubleshooting decisions.

• Merbromin Inhibits SARS-CoV-2 3CLpro

  2026-09-04

  The reference study used activity-based high-throughput screening of approximately 6,000 compounds to identify Merbromin as a selective inhibitor of the SARS-CoV-2 main protease, 3CLpro. Enzyme kinetics, binding assays, and molecular docking supported a mixed-type mechanism involving two proposed binding sites, providing a starting point for antiviral inhibitor development.

• Ribociclib Succinate: From Arrest to Translation

  2026-09-03

  Ribociclib succinate is more than a selective CDK4/6 tool: it is a translational probe for connecting RB-dependent cell-cycle control with reproducible phenotypes, exposure design, and biomarker-informed cancer research. This article outlines how to move from LEE011 succinate mechanism to rigorous validation while avoiding unsupported cross-domain conclusions.

• Carvedilol Phosphate in Hepatic IRI Workflows

  2026-09-03

  Carvedilol Phosphate provides a practical, high-purity way to perturb adrenergic GPCR signaling in hepatocyte, macrophage, and ischemia–reperfusion assays. This guide connects compound handling and assay design with the Arrb2–6-ketoLCA findings of a recent liver IRI study while clearly separating established evidence from testable extensions.

• TRPM3 Regulation by Neurosteroids and Primidone

  2026-09-02

  Yin et al. combine cryo-EM structures, electrophysiology, molecular dynamics, and mass spectrometry to define how pregnenolone sulfate, CIM0216, and primidone regulate the TRPM3 channel. The study connects ligand-binding sites with channel gating and disease-associated gain-of-function mutations, providing a structural framework for analgesic and neurodevelopmental drug discovery.

8091 records 1/540 page Next 12345 下5页 Last page